March 22nd 2024
In an interview with Targeted Oncology, Julie Chang, MD, discussed the minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma and the key findings from the trial.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Obintutuzumab Given Prior to Fixed-Duration Glofitamab Shows Durable Responses in R/R MCL
December 10th 2022Pretreatment with Obinutuzumab aids fixed-duration regimen of glofitamab in high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.
Read More
Understanding Recent Developments in Mantle Cell Lymphoma
November 23rd 2022In an interview with Targeted Oncology, Jia Ruan, MD, PhD, discussed the updates in the mantle cell lymphoma space, including understanding molecular pathogenesis and risk stratification for this patient population.
Read More
Examining Treatment Approaches in Relapsed/Refractory Mantle Cell Lymphoma
November 9th 2022In an interview with Targeted Oncology, Tycel Phillips, MD, discussed the many treatment options available and those that are being examined for patients with mantle cell lymphoma in the second-line setting.
Read More
Evaluating Effective Treatment Options and Strategies for Relapsed/Refractory Mantle Cell Lymphoma
October 15th 2022At the 2022 NCCN annual congress, Tycel Phillips, MD, discussed different strategies that can be effective as second-line treatments in various patients who have relapsed/refractory mantle cell lymphoma.
Read More
Increased Molecular Understanding Informs Mantle Cell Treatment Choices
October 2nd 2022Traditionally, MCL was dichotomized based on the age of the patient and their ability to tolerate intensive therapy, [but] now we have to take into consideration biological differences across patients that go well beyond age, says Andre H. Goy, MD.
Read More
Triplet Combination Addresses Unmet Need in Small Study Population With Mantle Cell Lymphoma
May 14th 2022Study results may indicate for a potential alternative treatment option to address the unmet needs for elderly patients with newly diagnosed mantle cell lymphoma, according to Michael Wang, MD.
Watch
Global ZILO-301 Study of Zilovertamab for MCL to Initiate in Q3 2022
April 28th 2022Oncternal Therapeutics announced it would terminate its study of ONCT-216 for patients with Ewing sarcoma and prioritize its phase 3 ZILO-301 study of zilovertamab plus ibrutinib for patients with relapsed/refractory mantle cell lymphoma.
Read More